Exagen Inc., a leader in autoimmune testing solutions, has announced the commencement of an underwritten public offering of its common stock. The company plans to grant the underwriter a 30-day option to purchase an additional 15% of the shares offered. Canaccord Genuity is serving as the sole bookrunner for this offering, which is subject to market conditions. The offering will be made under a shelf registration statement that was declared effective by the Securities and Exchange Commission. The final terms will be disclosed in a prospectus supplement to be filed with the SEC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.